Trial Profile
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia [EXTENSION OF 700216958]
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2013
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Registrational; Therapeutic Use
- 20 Feb 2013 New trial record